Massive study checks if diabetes Drug's heart benefits hold up outside the lab

This study looks at whether the heart-protective effects of the diabetes drug empagliflozin, seen in earlier clinical trials, also happen in a much larger, more diverse group of patients in real-world settings. Researchers will analyze health records from over 200,000 adults with type 2 diabetes who started taking empagliflozin or another diabetes drug. The goal is to see if the drug reduces risks like heart attack, stroke, and heart failure in everyday medical practice.